The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer see


Versions (2) ▾
  1. 11/21/11
  2. 3/27/14
Uploaded on:

March 27, 2014

No DOI assigned. To request one pleaselog in.
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

A Phase II Study of AZD4877 (a Novel Anti-mitotic DRKS00004052

Eligibility Bladder Cancer NCT00661609

Inclusion criteria
Exclusion criteria